The primary endpoint was the probability that the extended pulse and taper regimen would be superior in preventing recurrence ...

A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program. Risk of recurrent ...

Research found fecal microbiota transplantation (FMT) to be an optimal cost-effective treatment strategy for first and subsequent recurrent Clostridioides difficile infection (CDI), challenging ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff ...

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...

Please provide your email address to receive an email when new articles are posted on . “C. difficile is a major problem for people in the United States; it is the most common health care-associated ...

I am 78 years old and in fair health.

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

A recurrence of C. diff is common after an initial episode, with about 20% of people having a recurrence. A recurrence is ...

The MarketWatch News Department was not involved in the creation of this content. The Clostridioides difficile infection market is predicted to boost mainly owing to an increased aging population, ...